ALTAWEEL MICHAEL M ET AL: "Outcomes of Eyes with Lesions Composed of > 50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)", OPHTHALMOLOGY, vol. 122, no. 2, February 2015 (2015-02), pages 391-398, ISSN: 0161-6420(print) (B1)

BEAUMONT PAUL E ET AL: "Lesion morphology in age-related macular degeneration and its therapeutic significance", ARCHIVES OF OPHTHALMOLOGY, vol. 124, no. 6, June 2006 (2006-06), pages 807-812, ISSN: 0003-9950 (B1)

BROWN D M ET AL: "Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 116, no. 1, 1 January 2009 (2009-01-01), pages 57-65.e5, XP026623775, ISSN: 0161-6420, DOI: 10.1016/J.OPHTHA.2008.10.018 [retrieved on 2009-01-01] (B1)

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2013 (2013-06), ALTAWEEL MICHAEL ET AL: "Clinical Outcomes of Eyes with Neovascular Lesions Composed of > 50% Blood Treated with Anti-VEGF Therapy in the Comparison of AMD Treatments Trials (CATT)", Database accession no. PREV201800956959 & IOVS, vol. 54, no. 15, June 2013 (2013-06), page 4162, ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPH THALMOLOGY (ARVO); SEATTLE, WA, USA; MAY 05 -09, 2013 ISSN: 0146-0404(print) (B1)

DAVID M. BROWN ET AL: "Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration", NEW ENGLAND JOURNAL OF MEDICINE, vol. 355, no. 14, 5 October 2006 (2006-10-05), pages 1432-1444, XP055252324, US ISSN: 0028-4793, DOI: 10.1056/NEJMoa062655 (B1)

GUI-SHUANG YING ET AL: "Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration", OPHTHALMOLOGY., vol. 120, no. 1, 1 January 2013 (2013-01-01), pages 122-129, XP55252719, US ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2012.07.042 (B1)

WO-A2-02/062386 (B1)

JEFFREY S. HEIER ET AL: "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", OPHTHALMOLOGY, vol. 119, no. 12, 1 December 2012 (2012-12-01), pages 2537-2548, XP55138976, ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2012.09.006 (B1)

OHR MATTHEW ET AL: "Aflibercept in wet age-related macular degeneration: a perspective review.", THERAPEUTIC ADVANCES IN CHRONIC DISEASE JUL 2012, vol. 3, no. 4, July 2012 (2012-07), pages 153-161, ISSN: 2040-6223 (B1)

ROSENFELD PHILIP J ET AL: "Ranibizumab for neovascular age-related macular degeneration", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 355, no. 14, 5 October 2006 (2006-10-05), pages 1419-1431, XP002506588, ISSN: 0028-4793, DOI: 10.1056/NEJMOA054481 (B1)

Robert P. Finger ET AL: "Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration", SURVEY OF OPHTHALMOLOGY., vol. 59, no. 1, 1 January 2014 (2014-01-01), pages 1-18, XP55495272, XX ISSN: 0039-6257, DOI: 10.1016/j.survophthal.2013.03.009 (B1)

THE PIER STUDY GROUP REGILLO ET AL: "Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1", AMERICAN JOURNAL OF OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 145, no. 2, 25 January 2008 (2008-01-25), pages 239-248.e5, XP022433903, ISSN: 0002-9394, DOI: 10.1016/J.AJO.2007.10.004 (B1)

JAVIER ZARRANZ-VENTURA ET AL: "The Neovascular Age-Related Macular Degeneration Database", OPHTHALMOLOGY., vol. 121, no. 10, 1 October 2014 (2014-10-01), pages 1966-1975, XP55252725, US ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2014.04.026 (B1)